Journal «Angiology and Vascular Surgery» • 

2018 • VOLUME 24 • №4

Intralesional and perilesional application of an epidermal growth factor (Heberprot-P®) in diabetic foot ulcers. Part one

Jose Fernandez Montequin1, Llipsy Santiesteban Bonachea2, Jorge Berlanga Acosta3, et al.

1) Vascular Surgeon, National Institute of Angiology and Vascular Surgery,
2) Professor in the Biology Dpt., Medical University of Havana,
3) Center for Genetic Engineering and Biotechnology Havana, Cuba

For 15 years, from 2001, we began to apply Heberprot-P®, an injectable Epidermal Growth Factor (0.75 µg) created in the Center of Biotechnology, in Havana, Cuba. More than 159,000 patients were treated around the world, from 25 countries, with, with only 9-11% high-level amputations. In this paper, we discuss our experience in the treatment of the most complex diabetic foot ulcers cases for the last 15 years.

KEY WORDS: diabetes, diabetic foot syndrome, ulcer, treatment, Epidermal Growth Factor, Heberprot-P®.

P. 38-42

« Back